A Toxic Conformer of Aβ42 with a Turn at 22–23 is a Novel Therapeutic Target for Alzheimer’s Disease

Immunotherapy targeting Aβ42 is drawing attention as a possible therapeutic approach for Alzheimer’s disease (AD). Considering the significance of reported oligomerized Aβ42 species, selective targeting of the oligomer will increase the therapeutic efficacy. However, what kinds of oligomers are suit...

Descripción completa

Detalles Bibliográficos
Autores principales: Izuo, Naotaka, Kasahara, Chihiro, Murakami, Kazuma, Kume, Toshiaki, Maeda, Masahiro, Irie, Kazuhiro, Yokote, Koutaro, Shimizu, Takahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603611/
https://www.ncbi.nlm.nih.gov/pubmed/28924167
http://dx.doi.org/10.1038/s41598-017-11671-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603611/
https://www.ncbi.nlm.nih.gov/pubmed/28924167
http://dx.doi.org/10.1038/s41598-017-11671-6

Ejemplares similares